In AML, reduced 5hmC levels were observed in patients with or without a mutation in epigenetic modifiers, including TET2, IDH1, IDH2, and WT1, suggesting that other genes or posttranslational changes also regulated 5hmC levels [6,28,29,30,31,32,33]. This evidence concerns the gene IDH2 and acute myeloid leukemia.